Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sinopharm Group Co ( (HK:1099) ) just unveiled an announcement.
Sinopharm Group Co. Ltd. has announced the composition of its board of directors and the roles and functions of each member. The board includes non-executive, executive, and independent non-executive directors, with Zhao Bingxiang serving as the Chairman. The announcement also details the membership of five board committees, highlighting the company’s commitment to governance and strategic oversight.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a leading company in the pharmaceutical industry, focusing on the distribution and retail of pharmaceutical and healthcare products. It operates within the Chinese market and is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance.
Average Trading Volume: 7,869,082
Technical Sentiment Signal: Sell
Current Market Cap: HK$59.38B
For detailed information about 1099 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue